Merck’s 1992 Mevacor Statin/CoQ10 patent
The US Patent Office
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5082650.PN.&OS=PN/5082650&RS=PN/5082650
“Any pharmacological treatment, any drug treatment such as the clinical administration of MEVACOR to reduce hypercholesterolemia which reduces blood levels of CoQ.sub.10 and thereby reduces the energy-coupling and other roles of CoQ.sub.10 can be clinically detrimental such as to cardiac function and even life itself.”

Statin Drugs – A Critical Review of the Risk/Benefit Clinical Research
Joel M. Kauffman, Ph.D. Professor of Chemistry Emeritus
http://www.laleva.org/eng/2004/04/statin_drugs_a_critical_review_of_the_riskbenefit_clinical_research.html
“Besides cancer, the other side effects of statins listed were incomplete, and should have included constipation, myalgia, myopathy, polyneuropathy, liver and kidney damage, congestive heart failure and amnesia. Side-effects are usually said to affect 2-6% of patients. In fact, a recent meta-analysis noted side-effects in 20% of patients above the placebo rate (65% vs. 45%), and no change whatever in the all-cause death rate for atorvastatin. The PROSPER trial on pravastatin showed no change in the all-cause death rate, and increased cancer and stroke rates. Statins are commonly used at a dose to lower TC to < 160 mg/dL, a level noted in the report of a NHLBI conference to be associated with higher cancer rates….Statins decrease the body’s production of the essential coenzyme Q-10 and dolichol, among other things. Low Q-10 levels are strongly associated with congestive heart failure.”

Scary stuff. Good luck.